載入...
A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV-2 protects against disease and elicits neutralizing antibodies to wild-type and Delta variants
vaccines include mRNA-containing lipid nanoparticles or adenoviral vectors that encode the SARS-CoV-2 Several vaccines have been introduced to combat the coronavirus infectious disease-2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Current SARS-CoV-...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
格式: | Online Artículo Texto |
語言: | English |
出版: |
Cold Spring Harbor Laboratory
2022
|
主題: | |
在線閱讀: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820665/ https://www.ncbi.nlm.nih.gov/pubmed/35132418 http://dx.doi.org/10.1101/2021.06.28.450181 |